Retinal and Cognitive Dysfunction in Type 2 Diabetes

Cognitive Dysfunction Clinical Trial

— RECOGNISED  

Official title:

Retinal and Cognitive Dysfunction in Type 2 Diabetes: Unraveling the Common Pathways and Identification of Patients at Risk of Dementia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04281186
• Other study ID #: ECR-RET-2019-14
• Status: Active, not recruiting
• Start date: November 16, 2020
• Est. completion date: December 2023

Study information

• Verified date: August 2022
• Source: Hospital Universitari Vall d'Hebron Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences of subclinical pathology in patients with cognitive impairment. Our hypothesis is that the neurodegeneration of the retina will run in parallel to the neurodegeneration of the brain and, therefore, the signs of neurodysfunction in the retinal assessment will be more evident in those patients with rapid cognitive decline. Microangiopathy will also participate in cognitive decline and its specific role, as well as usefulness of retinal imaging, will be also examined.

This is a multinational and multicentre cross-sectional study and prospective, longitudinal cohort observational study.

Description:

The study consists of two main parts: a cross-sectional part and a longitudinal part, aimed at a) to determine whether functional and/or structural retinal biomarkers or circulating biomarkers are able to differentiate people with mild cognitive impairment (MCI) within the type 2 diabetes (T2D) population (the investigators will be able to do in the cross-sectional study, and, thus, use retina and/or blood biomarkers as a potential proxy to events taking place in the brain); b)to determine whether functional and/or structural retinal biomarkers or circulating biomarkers can be used to determine the speed of cognitive decline in people with T2D and MCI and those at higher risk of developing dementia.

The cross-sectional study will allow characterization of a large group of individuals with T2D (720 participants) and establish correlations between the various functional and structural retinal endpoints obtained and the presence/absence of mild cognitive impairment (MCI) and dementia. The cross-sectional study will allow identification of T2D patients with MCI; of these a group of 168 T2D patients with MCI and a group of T2D patients without MCI (n=63), which will act as a control group, will be then followed prospectively in the longitudinal cohort study to evaluate end points predictive of cognitive decline and dementia.

The primary objective is: to assess whether retinal sensitivity measured by microperimetry is able to predict cognitive decline and progression to dementia in MCI T2D patients.

The secondary objectives are:

1. To assess whether retinal sensitivity, measured by microperimetry, can identify individuals with MCI among people with T2D.

2. To assess whether eye fixation, measured by microperimetry, can identify individuals with MCI among people with T2D.

3. To assess whether eye fixation measured by microperimetry is able to predict rapid cognitive decline in T2D patients with MCI.

4. To define a T2D phenotype at high risk of developing dementia based on retinal imaging and functional retinal assessments.

5. To determine whether retinal imaging and functional retinal assessments may identify individuals with MCI among people with T2D.

6. To define a T2D phenotype at high risk to develop cognitive decline and dementia based on retinal imaging plus brain imaging.

7. To define a T2D phenotype at high risk to develop dementia based on retinal imaging plus brain imaging plus circulating biomarkers.

8. To establish a score to predict cognitive decline or progression from MCI to dementia based on the variables included in the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 509
• Est. completion date: December 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Type 2 diabetes

2. 65 years and older

3. Diabetes duration of at least 5 years

4. No overt retinopathy on fundus examination or fundus images, as determined by the evaluating ophthalmologist, in one or both eyes, and people with mild to moderate non-proliferative diabetic retinopathy (NPDR) as determined by the evaluating phthalmologists using fundus examination by slit-lamp biomicroscopy.

5. Able to provide informed consent

Prospective study:

In addition to the above, participants enrolled in the prospective longitudinal cohort study should fulfilled the following criteria:

1. Diagnosis of MCI confirmed by a neuropsychological test battery (NTB) and a specialized physician. For the control group the absence of MCI will also be confirmed by a neuropsychological test battery (NTB) and a specialized physician.

2. Diagnosis of no overt or mild to moderate NPDR (ETDRS DR level 20 to 47) confirmed by the reading centre.

Exclusion Criteria:

1. Previous history of stroke or neurodegenerative diseases.

2. Severe NPDR, Proliferative DR (PDR), Diabetic Macular Edema (DME) or other eye disorders affecting vision besides these complications of diabetic retinopathy (DR).

3. Previous laser photocoagulation.

4. Other diseases which may induce retinal neurodegeneration (e.g. glaucoma).

5. Subjects with a refractive error = ± 6 D.

6. Media opacities that preclude retinal imaging.

7. HbA1C > 10% (86 mmol/mol).

8. Severe systemic illness or personal circumstances that would not make it possible for patients to fulfil study protocols.

Prospective study:

In addition to the above, participants enrolled in the prospective longitudinal cohort study should fulfilled the following criteria:

1. Established dementia.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Microperimetry
• Retinal Function

Locations

Country	Name	City	State
Spain	Rafael Simó	Barcelona

Sponsors (21)

Lead Sponsor

Collaborator

Hospital Universitari Vall d'Hebron Research Institute

Alzheimer Europe, Anaxomics Biotech, Association for Innovation and Biomedical Research on Light and Image, Azienda Ospedaliero Universitaria Maggiore della Carita, Clinical Center of Montenegro, European Infrastructure for Translational Research, Genesis Biomed, Hospital Mutua de Terrassa, IDF Europe, Institut Catala de Salut, Ospedale San Raffaele, Oxurion, Queen's University, Belfast, UMC Utrecht, University of Cadiz, University of Medical Centre Amsterdam, University of Milan, University of Montenegro, University of Rome Tor Vergata, University of Southern Denmark

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retinal sensitivity	Assessed by microperimetry	48 month
Secondary	Retinal neurodysfunction/ neurodegeneration-1	Assessed by gaze fixation: areas BCEA63, BCEA95 and P1, P2 fixation points will be evaluated	48 month
Secondary	Retinal neurodysfunction/ neurodegeneration-2	Full-field photopic electroretinogram (ERG)	48 month
Secondary	Retinal neurodysfunction/ neurodegeneration-3	Spectral Domain Optical Coherence Tomography (SD-OCT): measurement of the retinal layers .	48 month
Secondary	Retinal vascular abnormalities-1	Assessed by Optical Coherence Tomography Angiography (OCT-A)	48 month
Secondary	Retinal vascular abnormalities-2	Ultra-wide field Fundus Fluorescein Angiography (FFA).	48 month
Secondary	Brain imaging-1	Assessed by Magnetic Resonance Imaging (MRI).	48 month
Secondary	Brain imaging-2	18 Fluoro-2-deoxyglucose-Positron Emission Tomography (18FDG-PET).	48 month
Secondary	Circulating biomarkers: Hypothesis free analysis	Blood samples: proteomics, complement system, inflammatory mediators, glial acidic fibrillary protein, HOMA-IR	48 month
Secondary	Geriatric Depression Scale	Geriatric Depression Scale (GDS-15): scores 0-4 normal, 5-8 mild depression, 9-11 moderate depression, 12-15 severe depression	48 month
Secondary	Quality of life: EQ-5D-3L	EQ-5D-3L questionnaire . The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.	48 month
Secondary	Visual Functioning Questionnaire	25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) . The NEI VFQ-25 contains a reduced number of items within each subscale of the original 51-item NEI VFQ. 13,29 The 12 subscales in the NEI VFQ-25 are general vision, near vision, distance vision, driving, peripheral vision, color vision, ocular pain, general health, and vision-specific role difficulties, dependency, social function, and mental health. The subscale scores are calculated by summing the relevant items and transforming the raw scores into a 0 to 100 scale where higher scores indicate better functioning or well-being. The total score of the NEI VFQ-25 is an average of 11 subscale scores, excluding the single-item general health subscale.	48 month
Secondary	Diabetes Specific Dementia Risk Score.	Diabetes Specific Dementia Risk Score (DSDRS). Briefly,the score is based on the age of the patients, history of any acute metabolic decompensation, the presence micro and/or macrovascular complications of the diabetes, depression and education level, obtaining a score ranged between -1 and 19. The higher the score, more risk of developing dementia at 10 years follow-up.	48 month